Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

BIO-key International Earnings Call: Key Takeaways

Bio-Key is pivoting to a high-margin software model, achieving 90% gross margins and debt-free status while leveraging Middle East expansion and agentic AI authentication.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthLicense revenue up 39%; EMEA revenue grew 39% with license fees doubling.
Mgmt ConfidenceHighly encouraged; targeting consistent profitability and positive cash flow by 2027.
Demand VisibilityPipeline includes seven-figure opportunities; eight new Middle East customers in seven months.
Margin TrendsGross margin improved sequentially to 90% from 77% a year ago.
Op. LeverageOperating loss reduced 8% as high-margin software offsets lower hardware sales.
Pricing PowerCharging more for lower quantity hardware units; three-year prepaid casino contract.
Vol vs PriceGrowth driven by license volume and shift to recurring software fees.
Segment GrowthSoftware license revenue is 86% of total; hardware revenue fell to $12k.
New ClientsCentral Bank of Jordan, Portugal National Security, and major U.S. casino.
Capex & DebtRetired remaining debt; effectively debt-free with $2.2M cash and $2.4M receivables.
RegulatoryUAE Central Bank phasing out SMS OTPs creates biometric tailwinds.
CommentaryFocusing on 'Identity Bound Biometrics' to secure rogue AI agents.
New LaunchesLaunched PortalGuard 7, Passkey Authenticator, and Saudi Arabian subsidiary establishment.

Growth

License revenue grew 39% year-over-year; total nine-month revenue rose 14% to $5.5M.

Outlook

Targeting profitability in Q1 2027 with $1.2M in expected license renewals.

Risks

Management pivoted on hardware slippage, citing 'dribbling' orders and civil ID program delays.

Source

The company's earnings call, NASDAQ: BKYI, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Bio Key International Inc: key numbers

Share price
$2.09Close, Nov 16
Market cap
$4.25M
Shares outstanding
2.04MLatest SEC cover page
Sector
Technology
Industry
Services-Prepackaged SoftwareSIC 7372

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Bio Key International Inc

All →
3:57 PM ET 10-Q
Financial Results ▶ Call

Bio Key International Q3 2026 Results: Net Loss of $886K, Loss Narrows

BIO-key International reported total revenues of $5.5M for the nine months ended September 30, 2026, an increase from $4.9M in the prior year period, driven by higher license fees. Despite the revenue growth, the company incurred a net loss available to common stockholders of $6.2M, significantly impacted by a $4.5M deemed dividend related to a warrant inducement.

Key figure
Net loss $886K
8:31 AM ET 8-K
Financial Results

Bio Key International Financial Results

BIO-key International reported Q3 2026 financial results, highlighted by a 39% increase in software license fee revenue to $1.3 million and a gross margin improvement to 90%. The company narrowed its quarterly net loss to $0.89 million and retired its remaining outstanding debt, leaving the firm effectively debt-free.

Term
Q3 2026

“Our Q3’26 results reflect the building strength of our core software business. Software license fee revenue grew 39% in Q3’26, offsetting variability in our more episodic hardware and services revenue and lifting gross margin to 90% from 77% a year ago.”

Mike DePasquale, CEO

“Year to date we have grown revenue by 14%, reduced our net loss by 42% and we retired our remaining note outstanding leaving us effectively debt free.”

Mike DePasquale, CEO
5:07 PM ET 8-K
Shareholder Meeting

Bio Key International Shareholder Meeting

BIO-key International reported the final voting results from its 2026 Annual Meeting of Stockholders, which concluded on October 30, 2026. Stockholders approved Proposal 4, authorizing the issuance of up to 1,236,668 shares of common stock upon the exercise of warrants from an August 2026 inducement transaction to comply with Nasdaq Listing Rule 5635(d).

4:48 PM ET 8-K
Shareholder Meeting

Bio Key International Shareholder Meeting

BIO-key International held its reconvened 2026 Annual Meeting of Stockholders on October 2, 2026, where shareholders elected five directors, ratified M&K CPAs, PLLC as auditors, and approved executive compensation on an advisory basis. The meeting was further adjourned until October 30, 2026, to allow more time for stockholders to vote on Proposal 4 regarding the issuance of common stock upon the exercise of warrants.

5:03 PM ET 8-K
Loan & Debt

Bio Key International Debt Financing Update with Streeterville Capital, LLC

BIO-key International entered into exchange agreements with Streeterville Capital to settle the remaining $416,315.80 balance of a 2025 secured promissory note. The company partitioned the debt into four new notes and immediately exchanged them for 247,805 shares of common stock. As a result of these transactions, the original note has been paid in full.

Counterparty
Streeterville Capital, LLC

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.